American journal of respiratory and critical care medicine
-
Am. J. Respir. Crit. Care Med. · Feb 2013
Randomized Controlled TrialInterferon-γ ELISPOT as a biomarker of treatment efficacy in latent tuberculosis infection: a clinical trial.
Biomarkers that can be used to evaluate new interventions against latent tuberculosis infection (LTBI) and predict reactivation TB disease are urgently required. ⋯ In contacts with LTBI, INH therapy plays no role in observed decreases in Mycobacterium tuberculosis antigen-specific T-cell responses over time. IFN-γ ELISPOT is probably not a useful biomarker of treatment efficacy in LTBI. Clinical trial registered with www.clinicaltrials.gov (NCT 00130325).
-
Am. J. Respir. Crit. Care Med. · Feb 2013
Randomized Controlled Trial Multicenter StudyRole of disease and macronutrient dose in the randomized controlled EPaNIC trial: a post hoc analysis.
Early parenteral nutrition to supplement insufficient enteral feeding during intensive care (early PN) delays recovery as compared with withholding parenteral nutrition for 1 week (late PN). ⋯ Early combined parenteral/enteral nutrition delayed recovery irrespective of severity of critical illness. No dose or type of macronutrient was found to be associated with improved outcome. Clinical trial registered with www.clinicaltrials.gov (NCT 00512122).